☰

Goli Samimi, Ph.D. - Publications

Affiliations: 
2004 University of California, San Diego, La Jolla, CA 
Area:
Cell Biology, Pharmacology
Tree Info Grants Similar researchers PubMed Report error

46 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Samimi G, Sathyamoorthy N, Tingen CM, Mazloomdoost D, Conroy J, Heckman-Stoddard B, Halvorson LM. Report of NCI and NICHD-Sponsored Workshop: Gynecology and Women's Health-Benign Conditions and Cancer. American Journal of Obstetrics and Gynecology. PMID 32835714 DOI: 10.1016/J.Ajog.2020.08.049  0.316
2020 Baker LA, Holliday H, Roden D, Krisp C, Wu SZ, Junankar S, Serandour AA, Mohammed H, Nair R, Sankaranarayanan G, Law AMK, McFarland A, Simpson PT, Lakhani S, Dodson E, ... ... Samimi G, et al. Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer. Breast Cancer Research : Bcr. 22: 63. PMID 32527287 DOI: 10.1186/S13058-020-01306-6  0.359
2020 Colvin EK, Howell VM, Mok SC, Samimi G, Vafaee F. Expression of lncRNAs in cancer-associated fibroblasts linked to patient survival in ovarian cancer. Cancer Science. PMID 32058624 DOI: 10.1111/Cas.14350  0.377
2019 Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Anglesio MS, Au-Yeung G, Böhm M, Bowtell DDL, Brand A, Chenevix-Trench G, Christie M, Chiew YE, ... ... Samimi G, et al. The molecular origin and taxonomy of mucinous ovarian carcinoma. Nature Communications. 10: 3935. PMID 31477716 DOI: 10.1038/S41467-019-11862-X  0.343
2019 Trivedi, Samimi G, Wright J, Holcomb K, Garber J, Horowitz N, Arber N, Friedman E, Wenham R, House M, Parnes H, Lee J, Abutaseh S, Vornik L, Heckman-Stoddard B, et al. Abstract OT2-09-01: Pilot study of denosumab in BRCA1/2 mutation carriers scheduling for risk-reducing salpingo-oophorectomy Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ot2-09-01  0.308
2018 Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. Ca: a Cancer Journal For Clinicians. PMID 29809280 DOI: 10.3322/Caac.21456  0.352
2018 Ring BZ, Murali R, Soslow RA, Bowtell DDL, Fereday S, DeFazio A, Traficante N, Kennedy CJ, Brand A, Sharma R, Harnett P, Samimi G. Transducin-Like Enhancer of Split 3 (TLE3) expression is associated with taxane sensitivity in non-serous ovarian carcinoma in a three-cohort study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 29531130 DOI: 10.1158/1055-9965.Epi-17-1101  0.422
2018 Murali R, Ring B, Soslow R, deFazio A, Kennedy C, Brand A, Harnett P, Sharma R, Samimi G. TLE3 expression is associated with favorable outcomes in taxane-treated patients with non-serous ovarian carcinoma: A multi-institution study Gynecologic Oncology. 149: 182. DOI: 10.1016/J.Ygyno.2018.04.414  0.327
2017 Vafaee F, Colvin EK, Mok SC, Howell VM, Samimi G. Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis. Scientific Reports. 7: 10374. PMID 28871211 DOI: 10.1038/S41598-017-10869-Y  0.345
2017 Samimi G, Minasian LM. Opportunistic salpingectomy: What about the role of the ovary in ovarian cancer? Cancer. 123: 1699-1702. PMID 28334415 DOI: 10.1002/Cncr.30525  0.337
2016 Sherman M, Drapkin R, Horowitz NS, Crum CP, Friedman S, Kwon J, Levine DA, Shih IM, Shoupe D, Swisher EM, Walker J, Trabert B, Greene MH, Samimi G, Temkin SM, et al. Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-grade Serous Carcinoma: A Review of the Evidence. Cancer Prevention Research (Philadelphia, Pa.). PMID 27221539 DOI: 10.1158/1940-6207.Capr-15-0384  0.304
2015 Moran-Jones K, Gloss BS, Murali R, Chang DK, Colvin EK, Jones MD, Yuen S, Howell VM, Brown LM, Wong CW, Spong SM, Scarlett CJ, Hacker NF, Ghosh S, Mok SC, ... ... Samimi G, et al. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget. PMID 26575166 DOI: 10.18632/Oncotarget.6082  0.39
2015 Moran-Jones K, Brown LM, Samimi G. INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models. Scientific Reports. 5: 11749. PMID 26138303 DOI: 10.1038/Srep11749  0.403
2015 Warton K, Samimi G. Methylation of cell-free circulating DNA in the diagnosis of cancer. Frontiers in Molecular Biosciences. 2: 13. PMID 25988180 DOI: 10.3389/Fmolb.2015.00013  0.31
2015 Colvin EK, Vafaee F, Mok SC, Howell VM, Samimi G. Abstract 2885: Differential expression of long non-coding RNAs in ovarian cancer-associated fibroblasts versus normal ovarian fibroblasts Cancer Research. 75: 2885-2885. DOI: 10.1158/1538-7445.Am2015-2885  0.371
2014 Gloss B, Moran-Jones K, Lin V, Gonzalez M, Scurry J, Hacker NF, Sutherland RL, Clark SJ, Samimi G. ZNF300P1 encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancer. Molecular Cancer. 13: 3. PMID 24393131 DOI: 10.1186/1476-4598-13-3  0.451
2014 Gloss BS, Samimi G. Epigenetic biomarkers in epithelial ovarian cancer. Cancer Letters. 342: 257-63. PMID 22245949 DOI: 10.1016/J.Canlet.2011.12.036  0.333
2013 Scott CL, Becker MA, Haluska P, Samimi G. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Frontiers in Oncology. 3: 295. PMID 24363999 DOI: 10.3389/Fonc.2013.00295  0.327
2013 Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, Mok SC. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Research. 73: 5016-28. PMID 23824740 DOI: 10.1158/0008-5472.Can-13-0023  0.362
2013 Moran-Jones K, Murali R, Chang DK, Wong CW, Spong SM, Hacker NF, Mok SC, Birrer MJ, Samimi G. Abstract B58: Connective tissue growth factor (CTGF) as a novel therapeutic target in high grade serous ovarian cancer Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-B58  0.41
2012 Samimi G, Ring BZ, Ross DT, Seitz RS, Sutherland RL, O'Brien PM, Hacker NF, Huh WK. TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 273-9. PMID 22194527 DOI: 10.1158/1055-9965.Epi-11-0917  0.356
2011 Samimi G, Wong C, Spong SM, Birrer MJ. Abstract 509: The CTGF antibody FG-3019 blocks CTGF-stimulated migration in ovarian cancer cells Cancer Research. 71: 509-509. DOI: 10.1158/1538-7445.Am2011-509  0.398
2010 Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ, Berkowitz RS, Mok SC. Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecologic Oncology. 119: 114-20. PMID 20619446 DOI: 10.1016/J.Ygyno.2010.05.029  0.357
2009 Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell. 16: 521-32. PMID 19962670 DOI: 10.1016/J.Ccr.2009.10.018  0.362
2007 Farley J, Ozbun L, Samimi G, Birrer MJ. Cell cycle and related protein. Disease Markers. 23: 433-43. PMID 18057526 DOI: 10.1155/2007/464712  0.344
2007 Samimi G, Ozbun L, Johnson ME, Mok SC, Birrer MJ. Biomarkers of mucinous tumors of the ovary. Disease Markers. 23: 389-96. PMID 18057522 DOI: 10.1155/2007/792356  0.311
2007 Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L, Bonome T, Birrer MJ, Berkowitz RS, Wong KK. Etiology and pathogenesis of epithelial ovarian cancer. Disease Markers. 23: 367-76. PMID 18057520 DOI: 10.1155/2007/474320  0.328
2007 Samimi G, Kishimoto S, Manorek G, Breaux JK, Howell SB. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Cancer Chemotherapy and Pharmacology. 59: 301-12. PMID 16770583 DOI: 10.1007/S00280-006-0271-0  0.54
2007 Bonome T, Samimi G, Randonovich M, Brady J, Ghosh S, Ng S, Mok SC, Birrer MJ. A stromal-associated gene expression signature predicting for survival in a series of patients with advanced high-grade serous ovarian cancer Journal of Clinical Oncology. 25: 5552-5552. DOI: 10.1200/Jco.2007.25.18_Suppl.5552  0.335
2006 Cheng TC, Manorek G, Samimi G, Lin X, Berry CC, Howell SB. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemotherapy and Pharmacology. 58: 384-95. PMID 16404635 DOI: 10.1007/S00280-005-0171-8  0.591
2006 Samimi G, Howell SB. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chemotherapy and Pharmacology. 57: 781-8. PMID 16170571 DOI: 10.1007/S00280-005-0121-5  0.703
2005 Safaei R, Katano K, Larson BJ, Samimi G, Holzer AK, Naerdemann W, Tomioka M, Goodman M, Howell SB. Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 756-67. PMID 15701866  0.754
2005 Samimi G, Manorek G, Castel R, Breaux JK, Cheng TC, Berry CC, Los G, Howell SB. cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemotherapy and Pharmacology. 55: 1-11. PMID 15378272 DOI: 10.1007/s00280-004-0819-9  0.521
2004 Safaei R, Holzer AK, Katano K, Samimi G, Howell SB. The role of copper transporters in the development of resistance to Pt drugs. Journal of Inorganic Biochemistry. 98: 1607-13. PMID 15458823 DOI: 10.1016/J.Jinorgbio.2004.05.006  0.779
2004 Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Howell SB. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4661-9. PMID 15269138 DOI: 10.1158/1078-0432.Ccr-04-0137  0.804
2004 Katano K, Safaei R, Samimi G, Holzer A, Tomioka M, Goodman M, Howell SB. Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4578-88. PMID 15240550 DOI: 10.1158/1078-0432.Ccr-03-0689  0.806
2004 Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, Howell SB. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Molecular Pharmacology. 66: 817-23. PMID 15229296 DOI: 10.1124/Mol.104.001198  0.796
2004 Samimi G, Katano K, Holzer AK, Safaei R, Howell SB. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Molecular Pharmacology. 66: 25-32. PMID 15213293 DOI: 10.1124/Mol.66.1.25  0.788
2004 Safaei R, Katano K, Samimi G, Naerdemann W, Stevenson JL, Rochdi M, Howell SB. Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemotherapy and Pharmacology. 53: 239-46. PMID 14648017 DOI: 10.1007/S00280-003-0736-3  0.64
2003 Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts DS, Howell SB. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 5853-9. PMID 14676106  0.654
2003 Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Molecular Pharmacology. 64: 466-73. PMID 12869652 DOI: 10.1124/Mol.64.2.466  0.802
2002 Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M, Howell SB. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Research. 62: 6559-65. PMID 12438251  0.793
2002 Mishima M, Samimi G, Kondo A, Lin X, Howell SB. The cellular pharmacology of oxaliplatin resistance. European Journal of Cancer (Oxford, England : 1990). 38: 1405-12. PMID 12091073 DOI: 10.1016/S0959-8049(02)00096-5  0.642
2002 Seely BL, Samimi G, Webster NJ. Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo. Bmc Cancer. 2: 15. PMID 12057025 DOI: 10.1186/1471-2407-2-15  0.323
2002 Los G, Yang F, Samimi G, Manorek G, Guerorguieva IM, Howell S, van Erp N, Breaux JK. Using mRNA expression profiling to determine anticancer drug efficacy. Cytometry. 47: 66-71. PMID 11774355 DOI: 10.1002/Cyto.10037  0.384
2001 Samimi G, Breaux J, Mishima M, Berry C, Howell S, Los G. Gene expression profiling of oxaliplatin-resistant cell lines Nature Genetics. 27: 84-84. DOI: 10.1038/87280  0.455
Show low-probability matches.